Akeso and Summit report ivonescimab meets overall survival endpoint in Phase 3 lung cancer trial
Akeso and its partner Summit said the Phase 3 trial of ivonescimab, a PD-1xVEGF bispecific antibody, has met its overall survival endpoint in a selected group of lung cancer patients. The announcement follows an interim overall survival result last year that had unsettled investors.
The updated data showed a statistically significant improvement in overall survival compared with the control arm, confirming the drug’s intended benefit in the studied indication. The trial met the pre-specified statistical criteria set by the sponsors.
The positive readout bolsters confidence in Akeso’s pipeline and may accelerate discussions with regulators about filing for approval. Investors are likely to reassess the company’s valuation in light of the new evidence.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trial”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that